Remote Ischemic Conditioning and Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG)

A Clinical Study on the Effect of Remote Ischemic Conditioning on Atrial Fibrillation and Outcome After Coronary Artery Bypass Grafting

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01107184

Acronym

RICO

Enrollment

191

Registered

2010-04-20

Start date

2010-01-31

Completion date

2016-02-29

Last updated

2018-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Remote ischemic conditioning, CABG surgery, Atrial fibrillation, Coronary Artery Bypass, Ischemic Preconditioning

Brief summary

Recent studies indicate that remote ischemic conditioning can protect the heart and other organs during cardiac surgery. The investigators aim to investigate whether such a stimulus can reduce the incidence of atrial fibrillation or other complications following coronary artery bypass surgery.

Interventions

PROCEDURERemote ischemic conditioning

Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.

PROCEDURESham

Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Elective on-pump CABG surgery * Informed consent

Exclusion criteria

* Prior cardiac surgery (Re-operations) * Prior atrial fibrillation * Use of class 1 or 3 anti arrhythmic medication or digoxin Use of intermittent aortic cross clamping during surgery * Age \<18 years * Left ventricular ejection fraction ≤30% * Serious pulmonary disease (resting pO2 \<90% at room air) * Renal failure (clearance \<30 ml/min as calculated using the Modification of Diet in Renal Disease formula) * Liver failure * Use of the sulfonylurea derivative glibenclamide (this drug is known to block any preconditioning stimulus

Design outcomes

Primary

Measure	Time frame
Post-operative atrial fibrillation	72 hours

Secondary

Measure	Time frame	Description
Major cardiovascular and cerebrovascular events	3 months, 6 months, 1 year	Major adverse events, i.e. death, acute coronary syndrome, stroke.
Length of stay	1 week on avarage	Duration of hospitalization and stay on the ICU

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026